Sugi Predict

Sugi Predict / Compounds / SCHEMBL2725354

SCHEMBL2725354

SCHEMBL2725354

CCOC(=O)c1nc(C(=O)O)cs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.54
▸ MAPT P10636 5/20 0.54
▸ NPC1 O15118 5/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ PLA2G4A P47712 2/20 0.54
▸ CYP1A2 P05177 2/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ GAA P10253 3/20 0.47
▸ POLB P06746 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ HSP90AA1 P07900 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9454202 0.90 RAB9A (0.66) RAB9AMAPTNPC1ALDH1A1MEN1
Bromopyruvate SCHEMBL21879942 0.89 PLA2G4A (0.45) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL4717848 0.87 RAB9A (0.62) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL9297546 0.87 RAB9A (0.54) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL19750761 0.85 RAB9A (0.56) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL22462630 0.85 MAPT (0.53) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL22462485 0.85 RAB9A (0.53) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL9297458 0.83 MAPT (0.50) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL17711445 0.83 MAPT (0.50) RAB9AMAPTNPC1ALDH1A1MEN1
SCHEMBL24983552 0.81 RAB9A (0.49) RAB9AMAPTNPC1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112979630-A Trifluoromethanols as Ror gamma t modulators 詹森药业有限公司 2021-06-18 — — CN claimed
EP-3354651-B1 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T JANSSEN PHARMACEUTICA NV (BE) 2021-01-06 — — EP claimed
US-10150762-B2 Trifluoromethyl alcohols as modulators of RORγt JANSSEN PHARMACEUTICA, NV (BE) 2018-12-11 — — US claimed
EP-3354651-A1 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T Janssen Pharmaceutica N.V. (BE) 2018-08-01 — — EP claimed
CN-107827841-A Trifluoromethyl alcohol as Ror γ t conditioning agents 詹森药业有限公司 2018-03-23 — — CN claimed
US-20170327492-A1 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt JANSSEN PHARMACEUTICA NV (BE) 2017-11-16 — — US claimed
EP-3364967-B1 FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2026-05-20 — — EP disclosed
US-12479834-B2 Phenol compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-11-25 — — US disclosed
EP-3365339-B1 NOVEL FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2025-07-16 — — EP disclosed
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
CN-118666823-A Compounds as Kif18A inhibitors 江苏星盛新辉医药有限公司 2024-09-20 — — CN disclosed
US-20240279233-A1 MACROCYCLIC TAK1 INHIBITORS AQILION AB (SE) 2024-08-22 — — US disclosed
US-12065430-B2 Indazole compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-08-20 — — US disclosed
US-7674801-B2 Alkyl urea substituted pyridines ASTRAZENECA AB (SE) 2010-03-09 — — US disclosed
CN-101627038-A Antibacterial polycyclic urea compounds ASTRAZENECA AB 2010-01-13 — — CN disclosed
EP-2102199-A1 ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS AstraZeneca AB (SE) 2009-09-23 — — EP disclosed
WO-2009058730-A1 DIAMIDO THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2009-05-07 — — WO disclosed
WO-2008068470-A1 ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS ASTRAZENECA AB (SE) 2008-06-12 — — WO disclosed
US-20080132546-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-06-05 — — US disclosed
WO-2008054702-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12065430-B2 Indazole compound or salt thereof RCOR3, H1-3, BICRA RAB9A 534/4885MAPT 1473/4885NPC1 1279/4885
US-20080132546-A1 CHEMICAL COMPOUNDS MRPL21, NISCH, ABCB11 RAB9A 1867/4885MAPT 1974/4885NPC1 207/4885
US-20170327492-A1 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt RORA, RORC, RORB RAB9A 3272/4885MAPT 3845/4885NPC1 2063/4885
US-10150762-B2 Trifluoromethyl alcohols as modulators of RORγt RORC, RORA, RORB RAB9A 3429/4885MAPT 2888/4885NPC1 1117/4885
US-12479834-B2 Phenol compound or salt thereof REN, MLX, MYB RAB9A 876/4885MAPT 3207/4885NPC1 2275/4885
US-20240279233-A1 MACROCYCLIC TAK1 INHIBITORS TAB1, TBK1, IRAK3 RAB9A 3291/4885MAPT 86/4885NPC1 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.